Perceived experiences of people with severe haemophilia A switching from factor VIII prophylaxis to emicizumab

1. Srivastava A, Santagostino E, Dougall A, et al. WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia 2020; 26(Suppl 6): 1–158. doi: 10.1111/hae.14046. SrivastavaA SantagostinoE DougallA WFH guidelines for the management of hemophilia, 3rd edition Haemophilia 2020 26 Suppl 6 1 158 10.1111/hae.14046 Open DOISearch in Google Scholar

2. Davari M, Gharibnaseri Z, Ravanbod R, Sadeghi A. Health status and quality of life in patients with severe hemophilia A: A cross-sectional survey. Hematol Rep 2019; 11(2): 7894. doi: 10.4081/hr.2019.7894. DavariM GharibnaseriZ RavanbodR SadeghiA Health status and quality of life in patients with severe hemophilia A: A cross-sectional survey Hematol Rep 2019 11 2 7894 10.4081/hr.2019.7894 Open DOISearch in Google Scholar

3. O’Hara J, Walsh S, Camp C, et al. The impact of severe haemophilia and the presence of target joints on health-related quality-of-life. Health Qual Life Outcomes 2018; 16(1): 84. doi: 10.1186/s12955-018-0908-9. O’HaraJ WalshS CampC The impact of severe haemophilia and the presence of target joints on health-related quality-of-life Health Qual Life Outcomes 2018 16 1 84 10.1186/s12955-018-0908-9 Open DOISearch in Google Scholar

4. Poenaru D, Sandulescu MI, Cinteza D. Intraarticular management of chronic haemophilic arthropathy. Biomed Rep 2023; 19(3): 59. doi: 10.3892/br.2023.1641. PoenaruD SandulescuMI CintezaD Intraarticular management of chronic haemophilic arthropathy Biomed Rep 2023 19 3 59 10.3892/br.2023.1641 Open DOISearch in Google Scholar

5. Gualtierotti R, Solimeno LP, Peyvandi F. Hemophilic arthropathy: Current knowledge and future perspectives. J Thromb Haemost 2021; 19(9): 2112–2121. doi: 10.1111/jth.15444. GualtierottiR SolimenoLP PeyvandiF Hemophilic arthropathy: Current knowledge and future perspectives J Thromb Haemost 2021 19 9 2112 2121 10.1111/jth.15444 Open DOISearch in Google Scholar

6. Witkop M, Guelcher C, Forsyth A, et al. Treatment outcomes, quality of life, and impact of hemophilia on young adults (aged 18–30 years) with hemophilia. Am J Hematol 2015; 90(S2): S3–S10. doi: 10.1002/ajh.24220. WitkopM GuelcherC ForsythA Treatment outcomes, quality of life, and impact of hemophilia on young adults (aged 18–30 years) with hemophilia Am J Hematol 2015 90 S2 S3 S10 10.1002/ajh.24220 Open DOISearch in Google Scholar

7. Wiley RE, Khoury CP, Snihur AWK, et al. From the voices of people with haemophilia A and their caregivers: Challenges with current treatment, their impact on quality of life and desired improvements in future therapies. Haemophilia 2019; 25(3): 433–440. doi: 10.1111/hae.13754. WileyRE KhouryCP SnihurAWK From the voices of people with haemophilia A and their caregivers: Challenges with current treatment, their impact on quality of life and desired improvements in future therapies Haemophilia 2019 25 3 433 440 10.1111/hae.13754 Open DOISearch in Google Scholar

8. Trindade GC, Viggiano LGL, Brant ER, et al. Evaluation of quality of life in hemophilia patients using the WHOQOL-bref and Haemo-A-Qol questionnaires. Hematol Transfus Cell Ther 2019; 41(4): 335–341. doi: 10.1016/j.htct.2019.03.010. TrindadeGC ViggianoLGL BrantER Evaluation of quality of life in hemophilia patients using the WHOQOL-bref and Haemo-A-Qol questionnaires Hematol Transfus Cell Ther 2019 41 4 335 341 10.1016/j.htct.2019.03.010 Open DOISearch in Google Scholar

9. Mahlangu J, Oldenburg J, Callaghan MU, et al. Health-related quality of life and health status in persons with haemophilia A with inhibitors: A prospective, multicentre, non-interventional study (NIS). Haemophilia 2019; 25(3): 382–391. doi: 10.1111/hae.13731. MahlanguJ OldenburgJ CallaghanMU Health-related quality of life and health status in persons with haemophilia A with inhibitors: A prospective, multicentre, non-interventional study (NIS) Haemophilia 2019 25 3 382 391 10.1111/hae.13731 Open DOISearch in Google Scholar

10. Oldenburg J, Tran H, Peyvandi F, et al. Health-related quality of life and health status in adolescent and adult people with haemophilia A without factor VIII inhibitors-A non-interventional study. Haemophilia 2021; 27(3): 398–407. doi: 10.1111/hae.14270. OldenburgJ TranH PeyvandiF Health-related quality of life and health status in adolescent and adult people with haemophilia A without factor VIII inhibitors-A non-interventional study Haemophilia 2021 27 3 398 407 10.1111/hae.14270 Open DOISearch in Google Scholar

11. von Drygalski A, Chowdary P, Kulkarni R, et al. Efanesoctocog alfa prophylaxis for patients with severe hemophilia A. N Engl J Med 2023; 388(4): 310–318. doi: 10.1056/NEJMoa2209226. von DrygalskiA ChowdaryP KulkarniR Efanesoctocog alfa prophylaxis for patients with severe hemophilia A N Engl J Med 2023 388 4 310 318 10.1056/NEJMoa2209226 Open DOISearch in Google Scholar

12. Hermans C, Reding MT, Astermark J, Klamroth R, Mancuso ME. Clinical studies of extended-half-life recombinant FVIII products for prophylaxis in adults and children: A critical review from the physician’s perspective. Crit Rev Oncol Hematol 2022; 174: 103678. doi: 10.1016/j.critrevonc.2022.103678. HermansC RedingMT AstermarkJ KlamrothR MancusoME Clinical studies of extended-half-life recombinant FVIII products for prophylaxis in adults and children: A critical review from the physician’s perspective Crit Rev Oncol Hematol 2022 174 103678 10.1016/j.critrevonc.2022.103678 Open DOISearch in Google Scholar

13. Blair HA. Emicizumab: a review in haemophilia A. Drugs 2019; 79(15): 1697–1707. doi: 10.1007/s40265-019-01200-2. BlairHA Emicizumab: a review in haemophilia A Drugs 2019 79 15 1697 1707 10.1007/s40265-019-01200-2 Open DOISearch in Google Scholar

14. Kitazawa T, Esaki K, Tachibana T, et al. Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens. Thromb Haemost 2017; 117(7): 1348–1357. doi: 10.1160/TH17-01-0030. KitazawaT EsakiK TachibanaT Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens Thromb Haemost 2017 117 7 1348 1357 10.1160/TH17-01-0030 Open DOISearch in Google Scholar

15. Oldenburg J, Mahlangu JN, Bujan W, et al. The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study. Haemophilia 2019; 25(1): 33–44. doi: 10.1111/hae.13618. OldenburgJ MahlanguJN BujanW The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study Haemophilia 2019 25 1 33 44 10.1111/hae.13618 Open DOISearch in Google Scholar

16. Young G, Liesner R, Chang T, et al. A multicenter, open-label, phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. Blood 2019; 134(24): 2127–2138. doi: 10.1182/blood.2019001869. YoungG LiesnerR ChangT A multicenter, open-label, phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors Blood 2019 134 24 2127 2138 10.1182/blood.2019001869 Open DOISearch in Google Scholar

17. Mahlangu J, Oldenburg J, Paz-Priel I, et al. Emicizumab prophylaxis in patients who have hemophilia A without inhibitors. N Engl J Med 2018; 379(9): 811–822. doi: 10.1056/NEJMoa1803550. MahlanguJ OldenburgJ Paz-PrielI Emicizumab prophylaxis in patients who have hemophilia A without inhibitors N Engl J Med 2018 379 9 811 822 10.1056/NEJMoa1803550 Open DOISearch in Google Scholar

18. Shima M, Nogami K, Nagami S, et al. A multicentre, open-label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors. Haemophilia 2019; 25(6): 979–987. doi: 10.1111/hae.13848. ShimaM NogamiK NagamiS A multicentre, open-label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors Haemophilia 2019 25 6 979 987 10.1111/hae.13848 Open DOISearch in Google Scholar

19. Yang R, Wang S, Wang X, et al. Prophylactic emicizumab for hemophilia A in the Asia-Pacific region: a randomized study (HAVEN 5). Res Pract Thromb Haemostast 2022; 6(2): e12670. doi: 10.1002/rth2.12670. YangR WangS WangX Prophylactic emicizumab for hemophilia A in the Asia-Pacific region: a randomized study (HAVEN 5) Res Pract Thromb Haemostast 2022 6 2 e12670 10.1002/rth2.12670 Open DOISearch in Google Scholar

20. Négrier C, Mahlangu J, Lehle M, et al. Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study. Lancet Haematol 2023; 10(3): e168–e177. doi: 10.1016/S2352-3026(22)00377-5. NégrierC MahlanguJ LehleM Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study Lancet Haematol 2023 10 3 e168 e177 10.1016/S2352-3026(22)00377-5 Open DOISearch in Google Scholar

21. Pipe SW, Collins P, Dhalluin C, et al. Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b, open-label trial. Blood 2024; 143(14): 1355–1364. doi: 10.1182/blood.2023021832. PipeSW CollinsP DhalluinC Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b, open-label trial Blood 2024 143 14 1355 1364 10.1182/blood.2023021832 Open DOISearch in Google Scholar

22. European Medicines Agency. HEMLIBRA^® solution for injection: Emicizumab. [Initial EU approval: 2018.] 2023. Available from https://www.ema.europa.eu/en/documents/product-information/hemlibra-epar-product-information_en.pdf (accessed November 2024). European Medicines Agency HEMLIBRA^® solution for injection: Emicizumab. [Initial EU approval: 2018.] 2023 Available from https://www.ema.europa.eu/en/documents/product-information/hemlibra-epar-product-information_en.pdf (accessed November 2024). Search in Google Scholar

23. Skinner MW, Negrier C, Paz-Priel I, et al. The effect of emicizumab prophylaxis on long-term, self-reported physical health in persons with haemophilia A without Factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies. Haemophilia 2021; 27(5): 854–865. doi: 10.1111/hae.14363. SkinnerMW NegrierC Paz-PrielI The effect of emicizumab prophylaxis on long-term, self-reported physical health in persons with haemophilia A without Factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies Haemophilia 2021 27 5 854 865 10.1111/hae.14363 Open DOISearch in Google Scholar

24. Hassan AS, Sherief LM, Hamdy M, Salamah A, El-Agamy OA. Physical activity limitations in children with severe haemophilia A. Does emicizumab make a difference? J Pak Med Assoc 2023; 73(Suppl 4): S31–S33. doi: 10.47391/JPMA.EGY-S4-10. HassanAS SheriefLM HamdyM SalamahA El-AgamyOA Physical activity limitations in children with severe haemophilia A. Does emicizumab make a difference? J Pak Med Assoc 2023 73 Suppl 4 S31 S33 10.47391/JPMA.EGY-S4-10 Open DOISearch in Google Scholar

25. Oldenburg J, Pipe SW, Mancuso ME, et al. Clinical experience of switching patients with severe hemophilia to rVIII-SingleChain or rIX-FP. Current Med Res Opin 2023; 39(2): 219–225. doi: 10.1080/03007995.2022.2116173. OldenburgJ PipeSW MancusoME Clinical experience of switching patients with severe hemophilia to rVIII-SingleChain or rIX-FP Current Med Res Opin 2023 39 2 219 225 10.1080/03007995.2022.2116173 Open DOISearch in Google Scholar

26. Thornburg CD, Coffin D. How clinicians and persons with hemophilia may approach shared decision-making. Expert Rev Hematol 2024; 17(6): 193–196. doi: 10.1080/17474086.2024.2353761. ThornburgCD CoffinD How clinicians and persons with hemophilia may approach shared decision-making Expert Rev Hematol 2024 17 6 193 196 10.1080/17474086.2024.2353761 Open DOISearch in Google Scholar

27. Graneheim UH, Lundman B. Qualitative content analysis in nursing research: concepts, procedures and measures to achieve trustworthiness. Nurse Educ Today 2004; 24(2): 105–112. doi: 10.1016/j.nedt.2003.10.001. GraneheimUH LundmanB Qualitative content analysis in nursing research: concepts, procedures and measures to achieve trustworthiness Nurse Educ Today 2004 24 2 105 112 10.1016/j.nedt.2003.10.001 Open DOISearch in Google Scholar

28. Elo S, Kyngäs H. The qualitative content analysis process. J Adv Nursing 2008; 62(1): 107–115. doi: 10.1111/j.1365-2648.2007.04569.x. EloS KyngäsH The qualitative content analysis process J Adv Nursing 2008 62 1 107 115 10.1111/j.1365-2648.2007.04569.x Open DOISearch in Google Scholar

29. O’Brien BC, Harris IB, Beckman TJ, Reed DA, Cook DA. Standards for reporting qualitative research: a synthesis of recommendations. Acad Med 2014; 89(9): 1245–1251. doi: 10.1097/ACM.0000000000000388. O’BrienBC HarrisIB BeckmanTJ ReedDA CookDA Standards for reporting qualitative research: a synthesis of recommendations Acad Med 2014 89 9 1245 1251 10.1097/ACM.0000000000000388 Open DOISearch in Google Scholar

30. Björkqvist J, Astermark J, Holme PA, et al. Non-interventional study on health-related quality of life, physical activity and bleeds in severe non-inhibitor hemophilia A patients with a bleeding phenotype on FVIII prophylaxis in the Nordics. Res Pract Thromb Haemost 2024; 8: 363–364. BjörkqvistJ AstermarkJ HolmePA Non-interventional study on health-related quality of life, physical activity and bleeds in severe non-inhibitor hemophilia A patients with a bleeding phenotype on FVIII prophylaxis in the Nordics Res Pract Thromb Haemost 2024 8 363 364 Search in Google Scholar

31. Weller SC, Vickers B, Bernard HR, et al. Open-ended interview questions and saturation. PLoS One 2018; 13(6): e0198606. doi: 10.1371/journal.pone.0198606. WellerSC VickersB BernardHR Open-ended interview questions and saturation PLoS One 2018 13 6 e0198606 10.1371/journal.pone.0198606 Open DOISearch in Google Scholar

32. Oka G, Roussel-Robert V, Levivien C, Lopez I, Pieragostini R. Assessment of the clinical perception, quality of life and satisfaction of patients with severe congenital haemophilia A without inhibitor after 1 year of emicizumab therapy. Haemophilia 2023; 29(3): 709–715. doi: 10.1111/hae.14755. OkaG Roussel-RobertV LevivienC LopezI PieragostiniR Assessment of the clinical perception, quality of life and satisfaction of patients with severe congenital haemophilia A without inhibitor after 1 year of emicizumab therapy Haemophilia 2023 29 3 709 715 10.1111/hae.14755 Open DOISearch in Google Scholar

33. Kempton C, Trask P, Parnes A, et al. Development and testing of the Satisfaction Questionnaire with Intravenous or Subcutaneous Hemophilia Injection and results from the Phase 3 HAVEN 3 study of emicizumab prophylaxis in persons with haemophilia A without FVIII inhibitors. Haemophilia 2021; 27(2): 221–228. doi: 10.1111/hae.14222. KemptonC TraskP ParnesA Development and testing of the Satisfaction Questionnaire with Intravenous or Subcutaneous Hemophilia Injection and results from the Phase 3 HAVEN 3 study of emicizumab prophylaxis in persons with haemophilia A without FVIII inhibitors Haemophilia 2021 27 2 221 228 10.1111/hae.14222 Open DOISearch in Google Scholar

34. Fletcher S, Jenner K, Holland M, Khair K. The lived experience of a novel disruptive therapy in a group of men and boys with haemophilia A with inhibitors: Emi & Me. Health Expect 2022; 25(1): 443–454. doi: 10.1111/hex.13404. FletcherS JennerK HollandM KhairK The lived experience of a novel disruptive therapy in a group of men and boys with haemophilia A with inhibitors: Emi & Me Health Expect 2022 25 1 443 454 10.1111/hex.13404 Open DOISearch in Google Scholar

35. Oladapo AO, Lu M, Walsh S, O’Hara J, Kauf TL. Inhibitor clinical burden of disease: a comparative analysis of the CHESS data. Orphanet J Rare Dis 2018; 13(1): 198. doi: 10.1186/s13023-018-0929-9. OladapoAO LuM WalshS O’HaraJ KaufTL Inhibitor clinical burden of disease: a comparative analysis of the CHESS data Orphanet J Rare Dis 2018 13 1 198 10.1186/s13023-018-0929-9 Open DOISearch in Google Scholar

36. Biasoli C, Baldacci E, Coppola A, et al. Promoting physical activity in people with haemophilia: the MEMO (Movement for persons with haEMOphilia) expert consensus project. Blood Transfus 2022; 20(1): 66–77. doi: 10.2450/2021.0138-21. BiasoliC BaldacciE CoppolaA Promoting physical activity in people with haemophilia: the MEMO (Movement for persons with haEMOphilia) expert consensus project Blood Transfus 2022 20 1 66 77 10.2450/2021.0138-21 Open DOISearch in Google Scholar

37. Kiialainen A, Niggli M, Kempton CL, et al. Effect of emicizumab prophylaxis on bone and joint health markers in people with haemophilia A without factor VIII inhibitors in the HAVEN 3 study. Haemophilia 2022; 28(6): 1033–1043. doi: 10.1111/hae.14642. KiialainenA NiggliM KemptonCL Effect of emicizumab prophylaxis on bone and joint health markers in people with haemophilia A without factor VIII inhibitors in the HAVEN 3 study Haemophilia 2022 28 6 1033 1043 10.1111/hae.14642 Open DOISearch in Google Scholar

38. DiBenedetti D, Neme D, Pan-Petesch B, et al. Patient experience with efanesoctocog Alfa for severe hemophilia A: results from the XTEND-1 phase 3 clinical study exit interviews. Clin Therapeutics 2024; S0149-2918(24): 272–278. doi: 10.1016/j.clinthera.2024.09.010. DiBenedettiD NemeD Pan-PeteschB Patient experience with efanesoctocog Alfa for severe hemophilia A: results from the XTEND-1 phase 3 clinical study exit interviews Clin Therapeutics 2024 S0149-2918 24 272 278 10.1016/j.clinthera.2024.09.010 Open DOISearch in Google Scholar

39. Lattimore SU, Hofstetter MT. Patient and family engagement during treatment change to emicizumab at a hemophilia treatment center. Blood 2019; 134(Supplement 1): :5796. doi: 10.1182/blood-2019-131030. LattimoreSU HofstetterMT Patient and family engagement during treatment change to emicizumab at a hemophilia treatment center Blood 2019 134 Supplement 1 5796 10.1182/blood-2019-131030 Open DOISearch in Google Scholar

40. Valentino LA BV, Negrier C, O’Mahony B, Bias V, Sannie T, Skinner MW. Personalising haemophilia management with shared decision making. J Haem Pract. 2021; 8(1): 69–79. doi: 10.17225/jhp00178. ValentinoLA BV NegrierC O’MahonyB BiasV SannieT SkinnerMW Personalising haemophilia management with shared decision making J Haem Pract 2021 8 1 69 79 10.17225/jhp00178 Open DOISearch in Google Scholar

41. van Balen EC, Wesselo ML, Baker BL, et al. Patient perspectives on novel treatments in haemophilia: A qualitative study. Patient 2020; 13(2): 201–210. doi: 10.1007/s40271-019-00395-6. van BalenEC WesseloML BakerBL Patient perspectives on novel treatments in haemophilia: A qualitative study Patient 2020 13 2 201 210 10.1007/s40271-019-00395-6 Open DOISearch in Google Scholar

42. Martinoli C, Della Casa Alberighi O, Di Minno G, et al. Development and definition of a simplified scanning procedure and scoring method for Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US). Thromb Haemost 2013; 109(6): 1170–1179. doi: 10.1160/TH12-11-0874. MartinoliC Della Casa AlberighiO Di MinnoG Development and definition of a simplified scanning procedure and scoring method for Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US) Thromb Haemost 2013 109 6 1170 1179 10.1160/TH12-11-0874 Open DOISearch in Google Scholar